



	Dr. Vinay Ch MD (Pathology & Chairman & Con		Dr. Yugam MD CEO & Consultant	(Pathology)	
NAME	: Dr. KULDEEP SINGH				
AGE/ GENDER	: 55 YRS/Male	PATI	ENT ID	: 1558096	
COLLECTED BY	:	REG.	NO./LAB NO.	: 012407230052	
REFERRED BY		REGISTRATION I		DATE : 23/Jul/2024 01:02 PM	
BARCODE NO.	: 01513688		ECTION DATE	: 23/Jul/2024 01:02 TM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE		: 23/Jul/2024 01:15PM : 23/Jul/2024 03:44PM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,				
Test Name		Value	Unit	Biological Reference interval	
GLYCOSYLATED HAEMO		HAEMATOI YCOSYLATED HAEMO 6.4		4.0 - 6.4	
WHOLE BLOOD by HPLC (HIGH PERFORN ESTIMATED AVERAGE F	IANCE LIQUID CHROMATOGRAPHY)	136.98	mg/dL	60.00 - 140.00	
	AS PER AMERICAN DIAE	ETES ASSOCIATION (ADA):			
	FERENCE GROUP		HEMOGLOGIB (HBAIC) ir	1 %	
	Non diabetic Adults >= 18 years				
Non diab	etic Adults >= 18 years		<5.7		
Non diab At R	etic Adults >= 18 years Risk (Prediabetes)		5.7 – 6.4		
Non diab At R	etic Adults >= 18 years		5.7 – 6.4 >= 6.5		
Non diab At R	etic Adults >= 18 years Risk (Prediabetes)	A	5.7 – 6.4 >= 6.5 ge > 19 Years		
Non diab At F Diag	etic Adults >= 18 years Risk (Prediabetes) gnosing Diabetes	A Goals of Therapy:	5.7 - 6.4 >= 6.5 ge > 19 Years < 7.0		
Non diab At F Diag	etic Adults >= 18 years Risk (Prediabetes)	A Goals of Therapy: Actions Suggested:	5.7 – 6.4 >= 6.5 ge > 19 Years		

2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate. 4. High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com
 www.koshealthcare.com




TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT





	Dr. Vinay Chopra MD (Pathology & Microbiolog Chairman & Consultant Patho		(Pathology)
NAME	: Dr. KULDEEP SINGH		
AGE/ GENDER	: 55 YRS/Male	PATIENT ID	: 1558096
COLLECTED BY	:	REG. NO./LAB NO.	: 012407230052
REFERRED BY	:	REGISTRATION DATE	: 23/Jul/2024 01:02 PM
BARCODE NO.	: 01513688	COLLECTION DATE	: 23/Jul/2024 01:15PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 23/Jul/2024 03:44PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CA	NTT	
Test Name	Value	Unit	Biological Reference interval







DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

V DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com







	٢	Dr. Vinay Chopr ID (Pathology & Mic Thairman & Consulta	robiology)	Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Dr. KULDEEF	SINGH			
AGE/ GENDER	: 55 YRS/Male		I	PATIENT ID	: 1558096
COLLECTED BY	:		F	REG. NO./LAB NO.	: 012407230052
REFERRED BY	:		F	REGISTRATION DATE	: 23/Jul/2024 01:02 PM
BARCODE NO.	:01513688		(COLLECTION DATE	: 23/Jul/2024 01:15PM
CLIENT CODE.	: KOS DIAGNOS	TIC LAB	H	REPORTING DATE	: 23/Jul/2024 02:53PM
CLIENT ADDRESS	: 6349/1, NICH	OLSON ROAD, AMB	ALA CANTT		
Test Name			Value	Unit	Biological Reference interval
		CLINICA	L CHEMIST	RY/BIOCHEMISTR	Y
		CREATININE	PHOSPHO	(INASE (CPK-NAC) TO	DTAL
CREATININE PHOSPH (CPK-NAC) by SPECTROPHOTOM			48.09	IU/L	24 - 190

Interpretation:-

1.Serum creatine kinase (CK) activity is greatly elevated, at some time during the course of the disease, in all types of muscular dystrophy, and especially so in Duchenne type, in which levels up to 50 times the upper limit of normal may be encountered.

2.In progressive muscular dystrophy, enzyme activity in serum is highest in infancy and childhood (7-10 years of age) and may be elevated long before the disease is clinically apparent.

3. Quite high values of CK are noted in viral myositis, polymyositis, and similar muscle diseases.

KOS Diagnostic Lab (A Unit of KOS Healthcare)

4. However, in neurogenic Parkinsonism, serum enzyme activity is normal. Very high activity is also encountered in malignant hyperthermia. *Significance:-*

1.An early rise in CK is also seen after an acute MI, with values peaking at 12 to 24 hours and falling back to normal in 3 to 4 days.

2.Although total CK activity has been used as a diagnostic test for MI, it has been replaced by the troponin T and I immunoassays, and is no longer the laboratory test choice for diagnosing and monitoring acute infarctions.

3.Serum CK activity may increase in patients with acute cerebrovascular disease or neurosurgical intervention and with cerebral ischemia.

4.Serum CK activity also demonstrates an inverse relationship with thyroid activity. About 60% of hypothyroid subjects show an average elevation of CK activity 5-fold over the upper reference limit; elevation of as high as 50-fold may also be found.

Note: Exercise and muscle trauma (contact sports, traffic accidents, intramuscular injections, surgery, convulsions, wasp or bee stings, and burns) can elevate serum creatine kinase values.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT





	Dr. Vinay Ch MD (Pathology & Chairman & Cor		Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Dr. KULDEEP SINGH			
AGE/ GENDER	: 55 YRS/Male	PATI	ENT ID	: 1558096
COLLECTED BY	:	REG. I	NO./LAB NO.	: 012407230052
REFERRED BY	:	REGIS	STRATION DATE	: 23/Jul/2024 01:02 PM
BARCODE NO.	:01513688	COLL	ECTION DATE	: 23/Jul/2024 01:15PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	: 23/Jul/2024 02:57PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
		ENDOCRINO	LOGY	
	COF	RTISOL: MORNING (8	8 A.M 10 A.M.)	
CORTISOL MORNING	(8 A.M 10 A.M.) ESCENCE IMMUNOASSAY)	11.245	μg/dL	4.26 - 24.85

2. Cortisol levels go up when the pituitary gland releases another hormone called adrenocorticotropic hormone (ACTH).

3.Most cortisol in the blood is bound to a protein; only a small percentage is "free" and biologically active. Blood cortisol testing evaluates both protein-bound and free cortisol while urine and saliva testing evaluate only free cortisol, which should correlate with the levels of free cortisol in the blood. Multiple blood and/or saliva cortisol levels collected at different times, such as at 8 am and 4 pm, can be used to evaluate both cortisol levels and diurnal variation. A 24-hour urine cortisol sample will not show diurnal variation; it will measure the total amount of unbound cortisol excreted in 24 hours.

CORTISOL FUNCTIONS:

1.It helps the body use sugar (glucose) and fat for energy (metabolism), and it helps the body manage stress.

KOS Diagnostic Lab (A Unit of KOS Healthcare)

- 2.Bone growth
- 3.Blood pressure control
- 4.Immune system function
- 5. Metabolism of fats, carbohydrates, and protein
- 6.Nervous system function
- 7.Stress response

THINGS TO KNOW ABOUT CORTISOL MEASUREMENT:

1.An increased or normal cortisol level just after waking along with a level that does not drop by bedtime suggests excess cortisol and Cushing syndrome. If this excess cortisol is not suppressed after an overnight dexamethasone suppression test, or if the 24-hour urine cortisol is elevated, or if the late-night salivary cortisol level is elevated, it suggests that the excess cortisol is due to abnormal increased ACTH production by the pituitary or a tumor outside of the pituitary or abnormal production by the adrenal glands. Additional testing will help to determine the exact cause.

2.If insufficient cortisol is present and the person tested responds to an ACTH stimulation test, then the problem is likely due to insufficient ACTH production by the pituitary. If the person does not respond to the ACTH stimulation test, then it is more likely that the problem is based in the adrenal glands. If the adrenal glands are underactive, due to pituitary dysfunction and/or insufficient ACTH production, then the person is said to have secondary adrenal insufficiency. If decreased cortisol production is due to adrenal damage, then the person is said to have primary adrenal insufficiency or Addison disease.

3. Once an abnormality has been identified and associated with the pituitary gland, adrenal glands, or other cause, then the health practitioner may use other testing such as CT (computerized tomography) or MRI (magnetic resonance imaging) scans to locate the source of the excess (such





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







	Dr. Vinay Chopra MD (Pathology & Microt Chairman & Consultant	G, /	(Pathology)
NAME	: Dr. KULDEEP SINGH		
AGE/ GENDER	: 55 YRS/Male	PATIENT ID	: 1558096
COLLECTED BY	:	REG. NO./LAB NO.	: 012407230052
REFERRED BY	:	REGISTRATION DATE	: 23/Jul/2024 01:02 PM
BARCODE NO.	: 01513688	COLLECTION DATE	: 23/Jul/2024 01:15PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 23/Jul/2024 02:57PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBAL	A CANTT	
Test Name		/alue Unit	Biological Reference interval

as a pituitary, adrenal, or other tumor) and to evaluate the extent of any damage to the glands.

4.Similar to those with adrenal insufficiency, people with a condition called congenital adrenal hyperplasia (CAH) have low cortisol levels and do not respond to ACTH stimulation tests. Cortisol measurement is one of many tests that may be used to help evaluate a person for CAH. 5.Heat, cold, infection, trauma, exercise, obesity, and debilitating disease can influence cortisol concentrations. Pregnancy, physical and emotional stress, and illness can increase cortisol levels. Cortisol levels may also increase as a result of hyperthyroidism or obesity. A number of drugs can also increase levels, particularly oral contraceptives (birth control pills), hydrocortisone (the synthetic form of cortisol), and spironolactone.

6. Adults have slightly higher cortisol levels than children do.

7. Hypothyroidism may decrease cortisol levels. Drugs that may decrease levels include some steroid hormones.

8.Salivary cortisol testing is being used more frequently to help diagnose Cushing syndrome and stress-related disorders but still requires specialized expertise to perform.

NOTE:

1.Normally, cortisol levels rise during the early morning hours and are highest about 7 a.m. They drop very low in the evening and during the early phase of sleep. But if you sleep during the day and are up at night, this pattern may be reversed. If you do not have this daily change (diurnal rhythm) in cortisol levels, you may have overactive adrenal glands. This condition is called Cushing's syndrome. 2.The timing of the cortisol test is very important because of the way cortisol levels vary throughout a day. If your doctor thinks you might make too much cortisol, the test will probably be done late in the day. If your doctor thinks you may not be making enough, a test is usually done in the morning.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com







NAME	: Dr. KULDEEP SINGH				
AGE/ GENDER	: 55 YRS/Male		PATIENT ID	: 1558096	
COLLECTED BY	:		REG. NO./LAB NO.	:0124072300	
REFERRED BY	:		REGISTRATION DATE	: 23/Jul/2024 01	
BARCODE NO.	: 01513688		COLLECTION DATE	: 23/Jul/2024 01	
CLIENT CODE. CLIENT ADDRESS	: KOS DIAGNOSTIC LAB : 6349/1, NICHOLSON ROAI). AMBALA CANT	REPORTING DATE	: 23/Jul/2024 03	:02PM
Test Name		Value	Unit	Biologi	cal Reference interval
		VI	TAMINS		
	V		HYDROXY VITAMIN D3		
/ΙΤΔΙΛΙΙΝ ΓΙ (25-μνι		95	ng/mL		NCY < 20.0
VITAMIN D (25-HYDROXY VITAMIN D3): SERU by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)		90	TIQ/TIL	DLI IGIL	DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0
by CLIA (CHEMILUMI	NESCENCE IMMUNOASSAY)			INSUFF	ICIENCY: 20.0 - 30.0
by CLIA (CHEMILUMII	NESCENCE IMMUNOASSAY)				ICIENCY: 20.0 - 30.0 IENCY: 30.0 - 100.0
	NESCENCE IMMUNOASSAY)			SUFFIC	
NTERPRETATION:		< 20		SUFFIC TOXICI	ENCY: 30.0 - 100.0
<u>Interpretation:</u> Def Insul	ICIENT:	< 20 21 - 29		SUFFIC TOXICI ng/mL ng/mL	ENCY: 30.0 - 100.0
<u>NTERPRETATION:</u> DEF INSUI PREFFEF	ICIENT: FFICIENT: RED RANGE:	21 - 29 30 - 100		SUFFIC TOXICI ng/mL ng/mL ng/mL	ENCY: 30.0 - 100.0
I <u>NTERPRETATION:</u> DEF INSU PREFFEF INTO)	ICIENT: FFICIENT: RED RANGE: CICATION: unds are derived from dietary er	21 - 29 30 - 100 > 100 rgocalciferol (fror	n plants, Vitamin D2), or ch	SUFFIC TOXICI ng/mL ng/mL ng/mL ng/mL	ENCY: 30.0 - 100.0 TY: > 100.0
<u>NTERPRETATION:</u> DEF INSUI PREFFEG INTOX I.Vitamin D compou conversion of 7- dih 2.25-OHVitamin D	ICIENT: FFICIENT: EED RANGE: ICATION: Inds are derived from dietary er vdrocholecalciferol to Vitamin I represents the main body resev	21 - 29 30 - 100 > 100 raocalciferol (fror D3 in the skin upo oir and transport	n plants, Vitamin D2), or ch	SUFFIC TOXICI ng/mL ng/mL ng/mL olecalciferol (from an	ENCY: 30.0 - 100.0 TY: > 100.0
<u>INTERPRETATION:</u> DEF INSUI PREFEEF INTO I.Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo	ICIENT: FFICIENT: ED RANGE: (ICATION: unds are derived from dietarv er vdrocholecalciferol to Vitamin I represents the main body resev bund by a transport protein whi	21 - 29 30 - 100 > 100 roocalciferol (fror 03 in the skin upo oir and transport le in circulation.	n plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar	SUFFIC TOXICI ng/mL ng/mL olecalciferol (from an usport form of Vitami	ENCY: 30.0 - 100.0 TY: > 100.0 nimals, Vitamin D3), or by D, being stored in adipose
<u>NTERPRETATION:</u> DEF INSU PREFFER INTO I.Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo S.Vitamin D plays a shosphate reabsorp	ICIENT: FFICIENT: ED RANGE: CATION: unds are derived from dietarv er vdrocholecalciferol to Vitamin I represents the main body resev bund by a transport protein whi primary role in the maintenanc tion, skeletal calcium depositio	21 - 29 30 - 100 > 100 raocalciferol (fror 03 in the skin upo oir and transport le in circulation. e of calcium hom n, calcium mobili	n plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar eostatis. It promotes calciu zation, mainly regulated by	SUFFIC TOXICI ng/mL ng/mL ng/mL olecalciferol (from an usport form of Vitami m absorption, renal parathyroid harmon	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH).
<u>NTERPRETATION:</u> DEF INSU PREFFER INTO> .Vitamin D compou conversion of 7- dih .25-OHVitamin D issue and tightly bo .Vitamin D plays a shosphate reabsorp .Severe deficiency DECREASED:	ICIENT: FFICIENT: RED RANGE: CICATION: unds are derived from dietarv er vdrocholecalciferol to Vitamin I represents the main body resev ound by a transport protein whi primary role in the maintenanc tion, skeletal calcium depositio may lead to failure to mineralize	21 - 29 30 - 100 > 100 raocalciferol (fror 03 in the skin upo oir and transport le in circulation. e of calcium hom n, calcium mobili	n plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar eostatis. It promotes calciu zation, mainly regulated by	SUFFIC TOXICI ng/mL ng/mL ng/mL olecalciferol (from an usport form of Vitami m absorption, renal parathyroid harmon	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH).
<u>NTERPRETATION:</u> DEF INSU PREFFEF INTO Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3.Vitamin D plays a ohosphate reabsorp J.Severe deficiency DECREASED: Lack of sunshine e	ICIENT: FFICIENT: RED RANGE: CICATION: unds are derived from dietary er vdrocholecalciferol to Vitamin I represents the main body resev bund by a transport protein whi primary role in the maintenanc tion, skeletal calcium depositio may lead to failure to mineralize xposure.	21 - 29 30 - 100 > 100 raocalciferol (fror 03 in the skin upo oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed c	n plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar eostatis. It promotes calciu zation, mainly regulated by	SUFFIC TOXICI ng/mL ng/mL ng/mL olecalciferol (from an usport form of Vitami m absorption, renal parathyroid harmon	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH).
<u>NTERPRETATION:</u> DEF INSU PREFFEG INTOX VItamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3.Vitamin D plays a shosphate reabsorp 4.Severe deficiency DECREASED: I.Lack of sunshine e 2.Inadeguate intake 3.Depressed Hepatic	ICIENT: FFICIENT: EED RANGE: INCATION: Inds are derived from dietarv er vdrocholecalciferol to Vitamin I represents the main body resev bund by a transport protein whi primary role in the maintenanc ition, skeletal calcium depositio may lead to failure to mineralize xposure. malabsorption (celiac disease c Vitamin D 25- hydroxylase acti	21 - 29 30 - 100 > 100 raocalciferol (fror 03 in the skin upor oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed c	n plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar eostatis. It promotes calciu zation, mainly regulated by	SUFFIC TOXICI ng/mL ng/mL ng/mL olecalciferol (from an usport form of Vitami m absorption, renal parathyroid harmon	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH).
<u>NTERPRETATION:</u> DEF INSU PREFFER INTO I.Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3.Vitamin D plays a bhosphate reabsorp 4.Severe deficiency DECREASED: I.Lack of sunshine e 2.Inadequate intake 3.Depressed Hepatit 5.Secondary to adva	ICIENT: FFICIENT: RED RANGE: Inds are derived from dietary er vdrocholecalciferol to Vitamin I represents the main body resev primary role in the maintenanc tion, skeletal calcium depositio may lead to failure to mineralize xposure. e, malabsorption (celiac disease c Vitamin D 25- hydroxylase action nced Liver disease	21 - 29 30 - 100 > 100 roocalciferol (fror O3 in the skin upo oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed of) ivity	n plants. Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar recostatis. It promotes calciu zation, mainly regulated by osteoid in bone, resulting in	SUFFIC TOXICI ng/mL ng/mL ng/mL olecalciferol (from an usport form of Vitami m absorption, renal parathyroid harmon	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH).
<u>NTERPRETATION:</u> DEF INSU PREFFER INTO I.Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3.Vitamin D plays a shosphate reabsorp 4.Severe deficiency DECREASED: I.Lack of sunshine e 3.Depressed Hepatit 3.Depressed Hepatit 3.Secondary to adva 5.Osteoporosis and 5.Enzyme Inducing of	ICIENT: FFICIENT: EED RANGE: INCATION: Inds are derived from dietarv er vdrocholecalciferol to Vitamin I represents the main body resev bund by a transport protein whi primary role in the maintenanc ition, skeletal calcium depositio may lead to failure to mineralize xposure. malabsorption (celiac disease c Vitamin D 25- hydroxylase acti	21 - 29 30 - 100 > 100 roocalciferol (fror O3 in the skin upo oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed of) ivity (Mild to Modera	n plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar reostatis. It promotes calciu zation, mainly regulated by osteoid in bone, resulting in	SUFFIC TOXICI ng/mL ng/mL olecalciferol (from an isport form of Vitami im absorption, renal parathyroid harmon rickets in children ar	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH). nd osteomalacia in adults.
INTERPRETATION: DEF INSUI PREFFEF INTO I.Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3.Vitamin D plays a bhosphate reabsorp 4.Severe deficiency DECREASED: I.Lack of sunshine e 2.Inadequate intake 3.Depressed Hepatif 4.Secondary to adva 5.Osteoporosis and 5.Enzyme Inducing of NCREASED: I. Hypervitaminosis	ICIENT: FFICIENT: RED RANGE: VICATION: unds are derived from dietary er vdrocholecalciferol to Vitamin D represents the main body resev pundb va transport protein whi primary role in the maintenanc titon, skeletal calcium depositio may lead to failure to mineralize xposure. e, malabsorption (celiac disease c Vitamin D 25- hydroxylase action nced Liver disease Secondary Hyperparathroidism drugs: anti-epileptic drugs like p D is Rare, and is seen only after	21 - 29 30 - 100 > 100 raocalciferol (fror 03 in the skin upor oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed of) ivity (Mild to Modera henytoin, phenol	n plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and tran teostatis. It promotes calciu zation, mainly regulated by osteoid in bone, resulting in te deficiency) parbital and carbamazepine	SUFFIC TOXICI ng/mL ng/mL olecalciferol (from an isport form of Vitami im absorption, renal parathyroid harmon rickets in children ar	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH). nd osteomalacia in adults.
INTERPRETATION: DEF INSU PREFFEF INTO INTO I.Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3.Vitamin D plays a obosphate reabsorp DECREASED: I.Lack of sunshine e 2.Inadequate intake 3.Depressed Hepatie 4.Secondary to adva 5.Osteoporosis and 5.Enzyme Inducing of NCREASED: I. Hypervitaminosis severe hypercalcem	ICIENT: FFICIENT: RED RANGE: VICATION: unds are derived from dietary er vdrocholecalciferol to Vitamin I represents the main body resev pund by a transport protein whi primary role in the maintenanc vtion, skeletal calcium depositio may lead to failure to mineralize xposure. e, malabsorption (celiac disease c Vitamin D 25- hydroxylase acti inced Liver disease Secondary Hyperparathroidism drugs: anti-epileptic drugs like p D is Rare, and is seen only after ia and hyperphophatemia.	21 - 29 30 - 100 > 100 raocalciferol (fror D3 in the skin upor oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed c) ivity (Mild to Modera henytoin, phenol r prolonged expos	m plants, Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar neostatis. It promotes calciu zation, mainly regulated by osteoid in bone, resulting in te deficiency) parbital and carbamazepine sure to extremely high dose	SUFFIC TOXICI ng/mL ng/mL olecalciferol (from an sport form of Vitami m absorption, renal parathyroid harmon rickets in children ar	ENCY: 30.0 - 100.0 TY: > 100.0 imals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH). nd osteomalacia in adults. nin D metabolism. nit occurs, it can result in
INTERPRETATION: DEF INSUI PREFFER INTO 1. Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3. Vitamin D plays a ohosphate reabsorp 4. Severe deficiency DECREASED: 1. Lack of sunshine e 2. Inadeguate intake 3. Depressed Hepatid 4. Secondary to adva 5. Osteoporosis and 6. Enzyme Inducing of NCREASED: 1. Hypervitaminosis Severe hypercalcem CAUTION: Replacem	ICIENT: FFICIENT: RED RANGE: Inds are derived from dietarv erver vdrocholecalciferol to Vitamin I represents the main body reseven punds vare derived from dietarv erver vdrocholecalciferol to Vitamin I prepresents the main body reseven punds vare derived from dietarv erver vdrocholecalciferol to Vitamin I prepresents the main body resevence pund by a transport protein white primary role in the maintenance tion, skeletal calcium deposition may lead to failure to mineralize xposure. e, malabsorption (celiac disease Secondary Hyperparathroidism drugs: anti-epileptic drugs like p D is Rare, and is seen only after ia and hyperphophatemia. ent therapy in deficient individu	21 - 29 <u>30 - 100</u> > 100 gocalciferol (fror 03 in the skin upo oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed c) ivity (Mild to Modera henytoin, phenol prolonged exposi- uals must be mon	n plants. Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar recostatis. It promotes calciu zation, mainly regulated by osteoid in bone, resulting in te deficiency) parbital and carbamazepine sure to extremely high dose itored by periodic assessme	SUFFIC TOXICI ng/mL ng/mL olecalciferol (from an isport form of Vitami isport form of Vitami is a sof Vitamin D. Wher ent of Vitamin D level	ENCY: 30.0 - 100.0 TY: > 100.0 Ty: > 100.0 animals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH). nd osteomalacia in adults. nin D metabolism. nit occurs, it can result in s in order to prevent
INTERPRETATION: DEF INSUI PREFFER INTO 1. Vitamin D compou conversion of 7- dih 2.25-OHVitamin D issue and tightly bo 3. Vitamin D plays a ohosphate reabsorp 4. Severe deficiency DECREASED: 1. Lack of sunshine e 2. Inadeguate intake 3. Depressed Hepatid 4. Secondary to adva 5. Osteoporosis and 6. Enzyme Inducing of NCREASED: 1. Hypervitaminosis Severe hypercalcem CAUTION: Replacem	ICIENT: FFICIENT: RED RANGE: Inds are derived from dietarv erver vdrocholecalciferol to Vitamin I represents the main body resevent punds vare derived from dietarv erver vdrocholecalciferol to Vitamin I represents the main body resevent pund by a transport protein white primary role in the maintenance tion, skeletal calcium deposition may lead to failure to mineralize xposure. e, malabsorption (celiac disease c Vitamin D 25- hydroxylase action inced Liver disease Secondary Hyperparathroidism drugs: anti-epileptic drugs like p D is Rare, and is seen only after ia and hyperphophatemia. ent therapy in deficient individu <i>Individuals as compare to white</i>	21 - 29 <u>30 - 100</u> > 100 gocalciferol (fror 03 in the skin upo oir and transport le in circulation. e of calcium hom n, calcium mobili e newly formed c) ivity (Mild to Modera henytoin, phenol prolonged exposi- uals must be mon	n plants. Vitamin D2), or ch on Ultraviolet exposure. form of Vitamin D and trar recostatis. It promotes calciu zation, mainly regulated by osteoid in bone, resulting in te deficiency) parbital and carbamazepine sure to extremely high dose itored by periodic assessme	SUFFIC TOXICI ng/mL ng/mL olecalciferol (from an isport form of Vitami isport form of Vitami is a sof Vitamin D. Wher ent of Vitamin D level	ENCY: 30.0 - 100.0 TY: > 100.0 Ty: > 100.0 animals, Vitamin D3), or by n D, being stored in adipose calcium absorption and e (PTH). nd osteomalacia in adults. nin D metabolism. nit occurs, it can result in s in order to prevent





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	55 YRS/Male	DATIL		
COLLECTED BY :		FAII	ENT ID	: 1558096
		REG. N	NO./LAB NO.	:012407230052
REFERRED BY :		REGIS	TRATION DATE	: 23/Jul/2024 01:02 PM
BARCODE NO.	01513688		ECTION DATE	: 23/Jul/2024 01:15PM
	KOS DIAGNOSTIC LAB		RTING DATE	: 23/Jul/2024 03:10PM
	6349/1, NICHOLSON ROAD, AM		NING DATE	. 23/ Jul/ 2024 03.101 M
CLIENI ADDRESS .	0349/1, MICHOLSON KOAD, AW	IDALA CANT I		
Test Name		Value	Unit	Biological Reference interval
INTERPRETATION:-	CENT MICROPARTICLE IMMUNOASSA	Y)		
	VITAMIN B12		DECREASED VITAMIN E	12
1.Ingestion of Vitamin C		1.Pregnancy		
2.Ingestion of Estrogen		2.DRUGS:Aspirin, Anti-convulsants, Colchicine		
				oleniene
3.Ingestion of Vitamin	A	3.Ethanol Igest	ion	
	A y		ion e Harmones	

the neurologic defects without macrocytic anemia.

6.Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states. 7.Follow-up testing for antibodies to intrinsic factor (IF) is recommended to identify this potential cause of vitamin B12 malabsorption. NOTE: A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.

*** End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



Page 7 of

TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT